Longitudinal evaluation of serum periostin levels in patients after large-artery atherosclerotic stroke: A prospective observational study

Xinwei He, Yuyan Bao, Yuguang Shen, En Wang, Weijun Hong, Shaofa Ke & Xiaoping Jin

Increasing evidence supports the involvement of periostin in the pathophysiological processes of stroke and atherosclerosis. The aim of this study was to assess circulating periostin levels at different times after large-artery atherosclerotic (LAA) stroke and their association with stroke. Serum periostin levels were measured using enzyme-linked immunosorbent assay on day 1 in 162 patients with LAA stroke and in 108 age- and sex-matched controls, on day 6 after stroke in 134 patients, and during the 4th week after stroke in 46 of the 162 patients. Stroke severity was determined using the National Institutes of Health Stroke Scale (NIHSS), and the stroke volume was measured. Outcome at 3 months was measured using the modified Rankin Scale (mRS). Our results indicated that periostin levels increased significantly on day 6 after stroke, and this increasing trend persisted for at least 4 weeks after the event. In addition, the increase in periostin levels was positively correlated with the NIHSS scores and stroke volume, but not with the mRS scores after adjusting for the NIHSS scores. In conclusion, these findings suggest that the increase in serum periostin levels observed after stroke may be associated with the stroke severity in patients with LAA stroke.

Stroke has become the leading cause of mortality and adult disability in China1. Ischaemic stroke (IS) accounts for approximately 80% of all stroke cases and causes a tremendous burden on health resources and families2. IS is characterized by the disruption of cerebral blood flow, leading to dysfunction of the affected area2. Early evaluations of severity and predictions of outcome are considered essential and critical in the treatment and care of patients with IS.

Periostin is a secreted extracellular matrix protein with known functions in osteology, oncology, and the cardiovascular and respiratory systems3,4. In general, periostin is expressed at low levels in tissues; however, periostin levels can increase rapidly under various adverse conditions3,5. Periostin expression is upregulated in the early stage of fracture healing and plays an important role in periosteal callus formation6. Additionally, periostin levels increase during the tissue remodelling process involved in wound repair, and periostin knock-out delays cutaneous wound healing7,8. Periostin has been shown to be rapidly secreted into infarcted tissue after acute myocardial infarction and is essential for the repair process9,10. Furthermore, previous studies have revealed the neuroprotective and neurogenic effects of periostin on IS models and cultured neurons11,12.

Recently, the capacity to measure serum periostin levels has prompted notable efforts to evaluate the severity and prognosis of specific diseases13–15. However, data on the periostin levels in patients with acute IS are not available.

In the present study, we compared the serum periostin levels measured in patients with large-artery atherosclerotic (LAA) stroke on day 1 and day 6 and during the 4th week after IS and the levels measured in age- and sex-matched controls. We also investigated the associations of periostin levels and changes in periostin levels with stroke severity and short-term outcomes after IS.

Results

Study population. The basic characteristics of the study subjects are shown in Table 1. Patients with LAA stroke had higher systolic blood pressure (SBP), fasting blood glucose (FBG) level, homocysteine level, and fibrinogen level and made up a larger percentage of smokers but had a lower percentage of dyslipidaemia than control subjects. No differences in the serum periostin levels were observed between the patients and controls (17.05 ± 4.95 ng/ml vs. 17.46 ± 6.60 ng/ml, p = 0.583, Fig. 1A).
but not with stroke volume (r = -0.026, p = 0.771). Furthermore, the increase in periostin levels observed from day 1 to the 4th week was correlated with the NIHSS scores on day 1 (r = 0.505; p < 0.001, Fig. 2C) and day 6 (r = 0.450, p = 0.002, Fig. 2D), along with the stroke volume (r = 0.352, p = 0.022).

Additionally, the increase in periostin levels observed during the first 6 days was higher in patients with a moderate-to-severe stroke than in patients with a mild stroke (NIHSS on day 1, p = 0.004, Fig. 3A; NIHSS on day 6, p = 0.015, Fig. 3B).

No associations were observed between serum periostin levels and functional outcomes after stroke. No differences in periostin levels (either on day 1 or day 6) were observed between patients with good outcomes and patients with poor outcomes (16.70 ± 5.04 ng/ml vs. 17.36 ± 4.53 ng/ml, p = 0.403). In addition, the change in periostin levels was positively correlated with the modified Rankin Scale (mRS) scores; however, after further adjustment for the NIHSS score, this relationship disappeared.

Discussion
In this study, we investigated the post-stroke time course of serum periostin levels. The serum periostin levels observed on day 1 after LAA stroke did not change compared with those of the healthy controls but did increase significantly on day 6 after the event. This increasing trend persisted for at least 4 weeks after stroke. The increased periostin levels were positively correlated with the NIHSS scores and stroke volume but were not correlated with the mRS scores after adjusting for the NIHSS scores.

Table 1. Baseline characteristics of the study population. Continuous variables are expressed as the means ± standard deviations (SDs) or the medians (interquartile ranges). Categorical values are given as frequencies (percentages). aRepresents the percentage in the hypertension population. bRepresents the percentage in the diabetic population. Abbreviations: LAA stroke, large-artery atherosclerotic stroke; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FBG, fasting blood glucose; CG, glucose; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycated haemoglobin; hs-CRP, high-sensitivity C-reactive protein; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale.

| Characteristic                | Patients (n = 162) | Controls (n = 108) | p value |
|------------------------------|-------------------|-------------------|---------|
| Age (years)                  | 71.7 ± 8.8        | 71.4 ± 9.5        | 0.816   |
| Male (%)                     | 105 (64.8)        | 70 (64.8)         | 1.000   |
| SBP (mmHg)                   | 152.9 ± 23.7      | 138.7 ± 19.3      | <0.001  |
| DBP (mmHg)                   | 77.7 ± 12.8       | 78.8 ± 8.5        | 0.407   |
| BMI (kg/m²)                  | 23.1 ± 3.3        | 23.5 ± 3.6        | 0.371   |
| FBG (mmol/L)                 | 5.30 (4.76, 6.07) | 5.05 (4.56, 5.74) | 0.016   |
| TG (mmol/L)                  | 1.34 (1.00, 1.71) | 1.41 (1.06, 1.97) | 0.082   |
| TC (mmol/L)                  | 4.42 (3.84, 5.17) | 4.35 (3.63, 5.25) | 0.401   |
| HDL-C (mmol/L)               | 1.18 ± 0.22       | 1.18 ± 0.23       | 0.946   |
| LDL-C (mmol/L)               | 2.54 (2.13, 3.26) | 2.69 (1.99, 3.36) | 0.506   |
| HbA1c (%)                    | 5.9 (5.5, 6.3)    | 5.7 (5.4, 6.2)    | 0.079   |
| Homocysteine (μmol/L)        | 13.0 (11.0, 17.2) | 11.8 (9.4, 14.8)  | 0.006   |
| Serum creatinine (μmol/L)    | 70.5 ± 17.2       | 70.0 ± 16.2       | 0.829   |
| Fibrinogen (g/L)             | 3.62 (3.19, 4.42) | 3.09 (2.79, 3.34) | <0.001  |
| Hs-CRP (mg/L)                | 3.4 (2.1, 5.9)    | 2.1 (1.7, 3.3)    | <0.001  |
| Hypertension                 | 119 (73.5)        | 75 (69.4)         | 0.473   |
| Diabetes mellitus            | 42 (25.9)         | 22 (20.4)         | 0.293   |
| Dyslipidaemia                | 67 (41.4)         | 62 (57.4)         | 0.010   |
| Smokers                      | 73 (45.1)         | 22 (20.4)         | <0.001  |
| Alcohol consumers            | 32 (19.8)         | 17 (15.7)         | 0.402   |
| Hypertension med use         | 40 (33.6e)        | 31 (41.3e)        | 0.277   |
| Diabetes med use             | 21 (50.0f)        | 14 (63.6e)        | 0.615   |
| NIHSS on day 1               | 4 (2.8)           | /                 | /       |
| mRS scores                   | 3 (2, 3)          | /                 | /       |

Serum periostin levels continuously increased after stroke for at least 4 weeks. The analysis of the time course of serum periostin levels in 134 patients showed higher periostin levels on day 6 after IS than on day 1 (day 6: 17.74 (14.81, 20.38) ng/ml vs. day 1: 15.73 (13.45, 18.94) ng/ml, p < 0.001, Fig. 1B). Furthermore, we analysed the periostin levels in 46 patients during the 4th week after IS and found that the periostin levels continuously increased at least up to the 4th week after the event (the 4th week: 22.11 (19.26, 26.11) ng/ml vs. day 1: 17.36 (14.90, 20.71) ng/ml, p < 0.001, Fig. 1C).

The increase in periostin levels observed after stroke was associated with stroke severity. The increase in periostin levels observed during the first 6 days was correlated with National Institutes of Health Stroke Scale (NIHSS) scores on both day 1 (r = 0.219, p = 0.011, Fig. 2A) and day 6 (r = 0.291, p = 0.001, Fig. 2B), but not with stroke volume (r = -0.026, p = 0.771). Furthermore, the increase in periostin levels observed from day 1 to the 4th week was correlated with the NIHSS scores on day 1 (r = 0.505; p < 0.001, Fig. 2C) and day 6 (r = 0.450, p = 0.002, Fig. 2D), along with the stroke volume (r = 0.352, p = 0.022).

Additionally, the increase in periostin levels observed during the first 6 days was higher in patients with a moderate-to-severe stroke than in patients with a mild stroke (NIHSS on day 1, p = 0.004, Fig. 3A; NIHSS on day 6, p = 0.015, Fig. 3B).
To the best of our knowledge, the present study constitutes the first evaluation of the serum periostin levels in humans after IS. Previous studies have demonstrated that the periostin levels in the brain increase during the acute, subacute, and chronic stages of IS in animal models\textsuperscript{11,12}. Periostin levels increase 24 h after cerebral ischaemia and remain high for up to 28 days afterward. Based on the results from the present study, serum periostin levels were stable on day 1 and then continued to increase through the 4th week after IS, similar to the changes in the intracranial levels observed in the animal models described above.

In addition, a recent study reported that serum periostin levels were significantly increased in patients with intracerebral haemorrhage (ICH) within 6 h after ICH compared with controls, and its levels were consistently increased within almost 24 h after ICH\textsuperscript{16}. It seems that the up trend of periostin levels is consistent after onset between ischaemic and haemorrhagic stroke, although the rising speed is different.

Previous studies found that increased periostin levels were associated with clinical severity and poor outcome in patients with traumatic brain injury\textsuperscript{17}, aneurysmal subarachnoid haemorrhage\textsuperscript{18}, and ICH\textsuperscript{16}. In the present study,
indicating that periostin may reverse cognitive deficits after IS. Thus, circulating periostin levels may be associated with ventricles of hypoxic-ischaemic rats was recently shown to significantly improve spatial learning and memory, and have been consistently shown to promote neovascularization and angiogenesis. Thus, in addition to the neuroprotective effects of periostin, the increase in serum periostin levels is likely involved in the vasculogenesis and angiogenesis of microvessels that occurs to protect against ischaemic injury after IS.

Incorporating the proliferation and differentiation of neural stem cells in the brain after ischaemic or haemorrhagic injury, which may rescue neuronal loss and restore brain function. An injection of periostin into the lateral ventricles of hypoxic-ischaemic rats was recently shown to significantly improve spatial learning and memory, indicating that periostin may reverse cognitive deficits after IS. Thus, circulating periostin levels may be associated with post-stroke cognitive impairment rather than the disability.

Angiogenesis plays an important role in the formation of new brain microvessels after IS. Periostin has been consistently shown to promote neovascularization and angiogenesis. Thus, in addition to the neuroprotective effects of periostin, the increase in serum periostin levels is likely involved in the vasculogenesis and angiogenesis of microvessels that occurs to protect against ischaemic injury after IS.

Regarding inflammation, periostin has been recognized as an inflammatory effector in asthma. A previous study found that periostin was upregulated in the cerebral cortex after experimental subarachnoid haemorrhage in mice and was responsible for early blood-brain barrier disruption and brain oedema formation through activating downstream signalling pathways, possibly because different periostin splicing variants show different functions depending on specific diseases.

Periostin continued to be expressed up to 28 days after cerebral ischaemia in various cells, such as astrocytes/microglia and neuronal progenitor cells. There is a possibility that periostin generated in the brain may leak into the circulation due to the breakdown of the blood-brain barrier that occurs after IS. However, the serum periostin levels were persistently increased for at least 4 weeks, whereas the damage to the blood-brain barrier gradually recovered. Cerebral ischaemia triggers biological reactions in both the affected brain region and the circulation. Therefore, it is unclear whether the increased periostin levels were predominantly derived from the breakdown of the blood-brain barrier or from other specific tissues or were due to overlap from both sources. Indeed, the sources of circulating periostin may include mesenchymal cells, such as bone, myocardium, and skin cells.

Furthermore, studies have reported that the intracerebroventricular administration of recombinant periostin exerts a protective effect after IS. Based on the consistent changes in periostin levels in the circulation and brain after IS, recombinant periostin may have therapeutic effects when administered via the circulation. Indeed, the application of recombinant periostin via the circulation improves cutaneous wounds, limb ischaemia, and myocardial infarction.

The daily routines and lifestyles of patients tend to change after IS, at least during the hospitalization and subsequent rehabilitation periods. Notably, periostin is required for the integrity and function of periodontium and bones, and the expression of periostin in these tissues increases in response to mechanical loading (such as occlusal loading, axial compression, and exercise) and decreases with reduced loading. During the acute phase and convalescence after IS, the motor function and exercise intensity of patients are relatively weak, which may attenuate the expression of periostin in bones; however, whether mechanical loading can affect periostin in the circulation has not been elucidated.

The present study had several limitations. First, our study demonstrated a direct correlation of the increase in periostin levels with NIHSS scores and stroke volume, while the correlation coefficients reflected weak or...
moderate correlation. Thus, the explanation needs to be more rigorous, and further multi-centre studies with larger sample sizes are needed to confirm our findings. Second, this work lacked long-term clinical prognostic data and post-stroke cognition evaluations, which may be associated with serum periostin levels or the changes in periostin levels. Third, although various alternatively spliced isoforms of periostin have been described in humans, little is known about their specific and even opposing functions. Indeed, the enzyme-linked immunosorbent assay (ELISA) kit used in our study detects all periostin isoforms present in the circulation. Hence, further studies are needed to develop new ELISA kits that distinguish the splicing variants. Finally, considering the clinical relevance of our study, we did not completely elucidate the pathophysiological mechanism. Nevertheless, this study extended the knowledge of the role of periostin in patients after IS.

In conclusion, we provided preliminary evidence that serum periostin levels continuously increase for at least 4 weeks after LAA stroke. The increased periostin levels are associated with stroke severity. However, further studies are needed to determine whether and how circulating periostin is involved in pathophysiological processes after LAA stroke. Further research should focus on clarifying the effects and sources of the increased circulating periostin levels and may also help us develop a novel clinical therapy for IS.

**Methods**

**Study subjects.** The study included 162 LAA stroke patients, who were consecutively recruited from the Department of Neurology at Taizhou Hospital, Zhejiang, China, from June 2014 to May 2015. Acute ischaemic stroke was diagnosed according to World Health Organization criteria. LAA stroke was defined according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria, reviewed by two neurological physicians. The following inclusion criteria were applied: first-time stroke, admission within 24 h after the event, and without thrombolysis or interventional therapy. The following exclusion criteria were applied: any previous history of stroke (including ischaemic stroke, intracerebral haemorrhage, or subarachnoid haemorrhage); severe coronary heart disease or arrhythmias; ischaemic peripheral arterial disease; chronic inflammatory, autoimmune, or haematological diseases; severe hepatic or renal insufficiencies or thyroid diseases; history of cancers; and previous surgical history (3 months). As a control group, 108 age-matched (blocks of 5 years) and sex-matched healthy individuals were recruited. They were free of the exclusion criteria.

Study was approved by the Medical Ethics Committee of Taizhou Hospital. All procedures were performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was provided by all participants before enrolment in the present study.

**Clinical protocol.** Stroke severity was assessed using the infarct volume and the NIHSS. Mild stroke was defined as an NIHSS score < 8, and moderate-to-severe stroke was defined as an NIHSS score ≥ 8, consistent with the existing literature. The infarct volume was evaluated in 151 patients using the initial diffusion-weighted imaging lesion volume and was calculated as the sum of the infarcted area of every slice multiplied by the slice thickness, based on several previous studies. Structured telephone follow-ups were conducted by one doctor who was blinded to the patients’ clinical information. A poor outcome was defined as a mRS score ≥ 2 at 3 months after stroke, as usual.

A flow chart of the study is shown in Fig. 4. Blood samples were collected on the morning after an overnight fast. The second blood samples were collected from 134 patients on day 6 after stroke. In the 162 LAA stroke patients, 5 patients died and 23 patients had been discharged or transferred within the first 6 days following admission. The characteristics of these subjects were not significantly different from those of the patients as a group (Supplementary Table S1). Furthermore, the third blood samples of 46 patients (from the 134 patients) were obtained on the 4th week during their reviews. The characteristics of these subjects were similar to those of the 162 patients, except for higher fibrinogen (Supplementary Table S2). The control subjects had a single blood sample on admission.

**Baseline clinical data collection and definition.** Baseline data, including demographic data, conventional risk factors, health history, and medications, were obtained from all participants. Height and weight were measured to calculate the body mass index.

Assessment of baseline vascular risk factors included hypertension (SBP/DBP ≥ 140/90 mm Hg based on the average of two measurements on admission, history of hypertension, or the use of antihypertensive medications), diabetes mellitus (FBG ≥ 7 mmol/L, diabetes history, or the use of antidiabetic treatments), dyslipidaemia (serum triglyceride ≥ 1.69 mmol/L, low-density lipoprotein ≥ 3.37 mmol/L, high-density lipoprotein cholesterol ≤ 0.91 mmol/L, or the use of lipid-lowering drugs), smokers (those who were currently smoking or had quit within the past year), and alcohol consumers (those who had moderate or heavy alcohol consumption ≥ 2 standard alcoholic beverages per day), as referenced in previous literature.

**Sample quantification and laboratory testing.** Samples were stored at −80 °C before testing. Periostin levels were measured using a commercially available ELISA kit (BioVendor, Brno, Czech Republic; catalogue number RAG019R). The inter- and intra-assay coefficients of variation were 4.54–9.90% and 6.22–8.60%, respectively. The mean minimum detectable dose was 15 pg/ml.

Biochemical measurements (e.g., FBG) were performed at the clinical laboratory in our hospital.

**Statistical analysis.** The Kolmogorov-Smirnov test was used for normality testing. Continuous data are expressed as the means ± standard deviations (SDs) or medians (interquartile ranges, IQRs). Categorical data are presented as counts and percentages. Comparisons between groups were made using Student’s t-test, the Mann-Whitney U test, or Pearson’s chi-squared statistic, as appropriate. Differences in the periostin levels at
different time points were assessed using the Wilcoxon signed-rank test. Pearson’s correlation test or Spearman’s rank correlation test was performed as appropriate. Data were analysed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). p < 0.05 was considered statistically significant.

Data availability. All data are fully available from the corresponding author on reasonable request.

References
1. Yang, G. et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 381, 1987–2015 (2013).
2. Donnan, G. A., Fisher, M., Macleod, M. & Davis, S. M. Stroke. Lancet 371, 1612–1623 (2008).
3. Conway, S. J. et al. The role of periostin in tissue remodeling across health and disease. Cell. Mol. Life Sci. 71, 1279–1288 (2014).
4. Yang, Z. et al. Circulating periostin in relation to insulin resistance and nonalcoholic fatty liver disease among overweight and obese subjects. Sci. Rep. 6, 37886 (2016).
5. Liu, A. Y., Zheng, H. & Ouyang, G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 37, 150–156 (2014).
6. Nakazawa, T. et al. Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J. Orthop. Res. 22, 520–525 (2004).
7. Nishiyama, T. et al. Delayed re-epithelialization in periostin-deficient mice during cutaneous wound healing. PLoS One 6, 0018410 (2011).
8. Elliott, C. G. et al. Periostin modulates myofibroblast differentiation during full-thickness cutaneous wound repair. J. Cell Sci. 125, 121–132 (2012).
9. Kuhn, B. et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat. Med. 13, 962–969 (2007).
10. Dorn, G. W. 2nd Periostin and myocardial repair, regeneration, and recovery. N. Engl. J. Med. 357, 1552–1554 (2007).
11. Shimamura, M. et al. Long-term expression of periostin during the chronic stage of ischemic stroke in mice. Hypertens. Res. 37, 494–499 (2014).
12. Shimamura, M. et al. Role of central nervous system periostin in cerebral ischemia. Stroke 43, 1108–1114 (2012).
13. Dellon, E. S. et al. Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosiophilic eosinophilic esophagitis. Aliment. Pharmacol. Ther. 44, 189–197 (2016).
14. Nuzzo, P. V. et al. Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa). Int. J. Mol. Sci. 16, 17181–17192 (2015).
15. Sakellariou, G. T. et al. Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. Rheumatology 54, 908–914 (2015).
16. Ji, W. J. et al. Association between serum periostin concentrations and outcome after acute spontaneous intracerebral hemorrhage. Clin. Chim. Acta 474, 23–27 (2017).
17. Dong, X. Q. et al. Serum periostin concentrations and outcomes after severe traumatic brain injury. Clin. Chim. Acta 471, 298–303 (2017).
18. Luo, W., Wang, H. & Ju, H. Increased concentration of serum periostin is associated with poor outcome of patients with aneurysmal subarachnoid hemorrhage. J. Clin. Lab. Anal. 2, 22389 (2018).
19. Ma, S. M. et al. Periostin promotes neural stem cell proliferation and differentiation following hypoxic-ischemic injury. PLoS One 10, e0123585 (2015).
20. Ikeda, T. Stem cells and neonatal brain injury. Cell Tissue Res. 331, 263–269 (2008).
21. Navarro-Sobrino, M. et al. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis 216, 205–211 (2011).
22. Hakuno, D. et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J. Clin. Invest. 120, 2292–2306 (2010).
23. Li, G. et al. Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. *Atherosclerosis* **208**, 358–365 (2010).
24. Lindner, V., Wang, Q., Conley, B. A., Friesel, R. E. & Vary, C. P. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. *Arterioscler. Thromb. Vasc. Biol.* **25**, 77–83 (2005).
25. Kim, B. R. et al. Therapeutic angiogenesis in a murine model of limb ischemia by recombinant periostin and its fascin 1 domain. *Biochim. Biophys. Acta* **9**, 14 (2014).
26. Izuhashi, K. et al. Roles of periostin in respiratory disorders. *Am. J. Respir. Crit. Care Med.* **193**, 949–956 (2016).
27. Liu, L. et al. Role of Periostin in Early Brain Injury After Subarachnoid Hemorrhage in Mice. *Stroke* **48**, 1108–1111 (2017).
28. Coutu, D. L. et al. Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. *J. Biol. Chem.* **283**, 17991–18001 (2008).
29. Wang, X. et al. Periostin contributes to the acquisition of multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells. *PLoS One* **8**, 372962 (2013).
30. Kudo, A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. *Cell. Mol. Life Sci.* **68**, 3201–3207 (2011).
31. Rios, H. F. et al. Mucin 1 mediates the effects of periostin expression on the production of PGE2 by A431 cells. *Biomed. Pharmacother.* **69**, 490–496 (2015).
32. Wen, W. et al. TGF-β1 and FAK regulate periostin expression in PDL fibroblasts. *J. Dent. Res.* **89**, 1439–1443 (2010).
33. Stroke–1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. *Stroke* **20**, 1407–1412 (1989).
34. Adams, H. P. Jr. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* **24**, 35–41 (1993).
35. Brott, T. et al. Measurements of acute cerebral infarction: a clinical examination scale. *Stroke* **20**, 864–870 (1989).
36. Kvistad, C. E. et al. Elevated admission blood pressure and stroke severity in acute ischemic stroke: the Bergen NORSTROKE Study. *Cerebrovasc. Dis.* **36**, 351–354 (2013).
37. Deguchi, I., Tanahashi, N. & Takao, M. Timing of treatment initiation with oral anticoagulants for acute ischemic stroke in patients with nonvalvular atrial fibrillation. *Circ. J.* **81**, 180–184 (2017).
38. Kang, Y. H. et al. Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels are associated with acute ischemic stroke severity. *Atherosclerosis* **240**, 228–233 (2015).
39. Carbone, F. et al. Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. *Eur. J. Clin. Invest.* **45**, 579–586 (2015).
40. Tang, S. C. et al. Cleaved but not endogenous secretory RAGE is associated with outcome in acute ischemic stroke. *Neurology* **86**, 270–276 (2016).
41. He, X. W. et al. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke. *Atherosclerosis* **253**, 22–28 (2016).
42. van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J. & van Gijn, J. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* **19**, 604–607 (1988).
43. Wang, Y. et al. Association of hypertension with stroke recurrence depends on ischemic stroke subtype. *Stroke* **44**, 1232–1237 (2013).

**Acknowledgements**

This work was supported by the Zhejiang Provincial Basic and Public Good Research Plan [grant number LGF18H090019], the Zhejiang Provincial Medicine and Health Research Foundation [grant number 2016KYA186 and 2017KY705], and the Taizhou Science and Technology Plan [grant number 162yw01 and 15yw01]. The authors are grateful to all of the volunteers who participated in this study.

**Author Contributions**

XJ. and X.WH. designed the experiments; X.WH., S.F.K. and Y.G.S. performed the experiments; Y.Y.B. and W.J.H. contributed to the specimen collection; X.WH. and E.W. analysed the data and wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-30121-5.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018